In 2015, there were 690,000 OUD ICU admissions with an average cost of $92,400 per patient, totaling an average cost to payers of $63.8B.
Buprenorphine is an FDA-approved medication that can help treat opioid addiction. It binds to opioid receptors and effectively blocks the signals from other opioids. It is proven to prevent cravings and withdrawal symptoms without an addictive high.
Today, patients have limited choices for treating their opioid addiction. They typically receive once-daily oral buprenorphine or buprenorphine/naloxone combination products (either tablets and sublingual film): formulations that are typically not administered by a physician and may be susceptible to abuse and diversion. These formulations are also highly susceptible to non-adherence: 58% of patients taking sublingual buprenorphine discontinue therapy within 30 days. Opioid-dependent patients who do not take at least 80% of their prescribed oral buprenorphine have over 10 times the risk of relapse than those who complete their prescribed course.
Braeburn is actively working to refile the New Drug Application for the company’s long acting weekly and monthly buprenorphine formulations (CAM2038). If approved, CAM2038 weekly and monthly formulations of buprenorphine will enable healthcare providers to treat patients with long-acting buprenorphine from the first day of their treatment, and to customize and tailor ongoing treatment to their patients’ needs.
Braeburn provides the healthcare provider with a flexible and customizable platform of addiction treatment medications that promote adherence and are expected to be less prone to abuse and diversion than daily addiction treatments.
Some injectables and implants may be less susceptible to abuse and diversion because they remain in healthcare provider control until administered.
Because the physician administers each dose, it is possible to achieve significant adherence during the prescribed dosage period. Braeburn’s weekly and monthly formulations are flexible and customizable: they can match the health care provider’s existing patient protocol and can be tailored to the needs of individual patients.
At Braeburn, we continually seek to reevaluate the way we work together to create an environment that redefines treatment for a vastly underserved patient population. Our core focus dedicated to advancing our pipeline of innovative treatments, but we also appreciate and accept our role as an emerging leader and voice in addiction and our other patient communities. We say that Braeburn thinks beyond what has been done…to imagine what can be done…and what is possible. For those who share this vision, we have created paths to help support and enable achieving what is possible.
Beyond our primary mission of investing in the clinical development and commercialization of our products and candidates, we may also choose to support community or healthcare programs which we consider consistent with our corporate mission and focus. Requests are considered on an individual basis and from US applicants only.
In 2015, there were 690,000 OUD ICU admissions with an average cost of $92,400 per patient, totaling an average cost to payers of $63.8B.
Buprenorphine is an FDA-approved medication that can help treat opioid addiction. It binds to opioid receptors and effectively blocks the signals from other opioids. It is proven to prevent cravings and withdrawal symptoms without an addictive high.
Today, patients have limited choices for treating their opioid addiction. They typically receive once-daily oral buprenorphine or buprenorphine/naloxone combination products (either tablets and sublingual film): formulations that are typically not administered by a physician and may be susceptible to abuse and diversion. These formulations are also highly susceptible to non-adherence: 58% of patients taking sublingual buprenorphine discontinue therapy within 30 days. Opioid-dependent patients who do not take at least 80% of their prescribed oral buprenorphine have over 10 times the risk of relapse than those who complete their prescribed course.
Braeburn is actively working to refile the New Drug Application for the company’s long acting weekly and monthly buprenorphine formulations (CAM2038). If approved, CAM2038 weekly and monthly formulations of buprenorphine will enable healthcare providers to treat patients with long-acting buprenorphine from the first day of their treatment, and to customize and tailor ongoing treatment to their patients’ needs.
Braeburn provides the healthcare provider with a flexible and customizable platform of addiction treatment medications that promote adherence and are expected to be less prone to abuse and diversion than daily addiction treatments.
Some injectables and implants may be less susceptible to abuse and diversion because they remain in healthcare provider control until administered.
Because the physician administers each dose, it is possible to achieve significant adherence during the prescribed dosage period. Braeburn’s weekly and monthly formulations are flexible and customizable: they can match the health care provider’s existing patient protocol and can be tailored to the needs of individual patients.
At Braeburn, we continually seek to reevaluate the way we work together to create an environment that redefines treatment for a vastly underserved patient population. Our core focus dedicated to advancing our pipeline of innovative treatments, but we also appreciate and accept our role as an emerging leader and voice in addiction and our other patient communities. We say that Braeburn thinks beyond what has been done…to imagine what can be done…and what is possible. For those who share this vision, we have created paths to help support and enable achieving what is possible.
Beyond our primary mission of investing in the clinical development and commercialization of our products and candidates, we may also choose to support community or healthcare programs which we consider consistent with our corporate mission and focus. Requests are considered on an individual basis and from US applicants only.
KEY FACTS ABOUT BRAEBURN RX INC.
-
US Businesses
-
Companies in Florida
-
Leon County Companies
- Company name
- BRAEBURN RX INC.
- Status
- Active
- Filed Number
- F16000001981
- FEI Number
- 461031785
- Date of Incorporation
-
April 26, 2016
Age - 9 years
- Home State
- DE
- Company Type
- Foreign for Profit
CONTACTS
- Website
- http://braeburnpharmaceuticals.com
- Phones
-
(609) 751-5375
(844) 859-6341
BRAEBURN RX INC. NEAR ME
- Principal Address
- 450 Plymouth Rd,
Plymouth Meeting,
PA,
19462,
US
See Also